Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ambulatory glucose profile

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Ambulatory glucose profile. Displaying page 1 of 1.
    EudraCT Number: 2011-005274-30 Sponsor Protocol Number: UCL_2011_DIDo Start Date*: 2012-08-27
    Sponsor Name:Université catholique de Louvain
    Full Title: Efficacy and safety of a Double Icodextrin Dose in elderly incident CAPD patients on incremental Peritoneal Dialysis therapy: the DIDo study
    Medical condition: Patients with chronic renal failure who are starting a Continuous Ambulatory Peritoneal Dialysis (CAPD) as first line dialyse.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004865 10007184 CAPD LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005300-13 Sponsor Protocol Number: IP-003-05 Start Date*: 2007-05-29
    Sponsor Name:IPERBOREAL PHARMA
    Full Title: Efficiency of L-Carnitine-containing Peritoneal Dialysis Solutions for diurnal exchanges in diabetes type 2 CAPD patients with ESRD on glucose metabolism. Randomized, parallel study compared versus...
    Medical condition: Patients affected by End Stage Renal Disease (ESRD) treated with Continuous Ambulatory Peritoneal Dialysis (CAPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038444 Renal failure chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005298-23 Sponsor Protocol Number: IP-002-05 Start Date*: 2007-03-12
    Sponsor Name:IPERBOREAL PHARMA
    Full Title: Efficiency of L-Carnitine-containing Peritoneal Dialysis Solutions for diurnal exchanges in CAPD Patients with ESRD on Glucose and Lipid Metabolisms. Randomized, Parallel Study Compared versus a St...
    Medical condition: Patients affected by End stage renal disease ESRD treated with Continuous Ambulatory Peritoneal Dialysis CAPD .
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038444 Renal failure chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022073-34 Sponsor Protocol Number: PST2238-DM-10-001 Start Date*: 2010-12-29
    Sponsor Name:CVIE THERAPEUTICS COMPANY LIMITED
    Full Title: Antihypertensive effect of different doses of Rostafuroxin in comparison with Losartan, assessed by office and ambulatory blood pressure monitoring in a hypertensive population selected according t...
    Medical condition: Patients with arterial hypertension, bearers of a specific genetic profile (Presence of at least one mutated genotype or combination of genotypes corresponding to the list provided in Genetic Profi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002963-40 Sponsor Protocol Number: IDAPADM1 Start Date*: 2015-10-26
    Sponsor Name:Dra Cristina Avendaño Sola
    Full Title: Impact of treatment with Dapagliflozin (SGLT2 inhibitor) in metabolic control and glycemic pattern in type 1 diabetic patients
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000501-29 Sponsor Protocol Number: CRC-ER-1_2007 Start Date*: 2008-10-27
    Sponsor Name:University Hospital of Erlangen
    Full Title: Low grade albuminuria: reaching a new target for irbesartan
    Medical condition: low grade albuminuria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001580 Albuminuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001227-45 Sponsor Protocol Number: PHT/2017/20 Start Date*: 2017-06-12
    Sponsor Name:Portsmouth Hospitals NHS Trust
    Full Title: Comparison of ambulatory glucose profile prior to and during pancreatic enzyme replacement therapy in patients with diabetes and pancreatic exocrine insufficiency: a single-arm phase IV trial
    Medical condition: Type 1 diabetes and type 2 diabetes mellitus Pancreatic exocrine insufficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    20.1 10027433 - Metabolism and nutrition disorders 10045228 Type I diabetes mellitus LLT
    20.0 100000004856 10033628 Pancreatic insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002005-36 Sponsor Protocol Number: RM-493-015 Start Date*: 2017-10-30
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Leptin Receptor (LEPR) Deficiency...
    Medical condition: Early Onset Leptin Receptor (LEPR) Deficiency Obesity due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005288-17 Sponsor Protocol Number: ESR-15-10964 Start Date*: 2016-04-05
    Sponsor Name:ΕΛΛΗΝΙΚΗ ΕΤΑΙΡΕΙΑ ΙΑΤΡΙΚΗΣ ΕΚΠΑΙΔΕΥΣΗΣ (Hellenic Society of Medical Education)
    Full Title: A study of the effects of dapagliflozin on ambulatory aortic pressure, arterial stiffness and urine albumin excretion in patients with type 2 diabetes.
    Medical condition: A study of the effects of dapagliflozin on ambulatory aortic pressure, arterial stiffness and urine albumin excretion in patients with type 2 diabetes mellitus.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10029505 Non-insulin-dependent diabetes mellitus LLT
    18.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002320-83 Sponsor Protocol Number: RM-493-012 Start Date*: 2016-09-28
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset POMC Deficiency Obesi...
    Medical condition: Early onset pro-opiomelanocortin deficiency obesity
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-002309-36 Sponsor Protocol Number: PDY15010 Start Date*: 2018-02-21
    Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
    Full Title: A randomized, double-blind, parallel-group, 2-treatment multiple dose study to assess the intestinal, metabolic and cardiovascular effects of an 8 weeks treatment with sotagliflozin QD as compared ...
    Medical condition: Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004607-11 Sponsor Protocol Number: Start Date*: 2006-02-23
    Sponsor Name:Hopital Erasme
    Full Title: Prospective, randomized, long-term study compairing a Neoral (C-0h monitoring)-based steroid-free to an everolimus-myfortic based, calcineurin-inhibitor-free immunosuppressive treatment on graft fu...
    Medical condition: “De novo” renal transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004033-15 Sponsor Protocol Number: B2C108562 Start Date*: 2006-09-29
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H (100 and 400...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001713-14 Sponsor Protocol Number: PROCEED Start Date*: 2011-05-18
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A PROSPECTIVE, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE ANTIPROTEINURIC EFFECT OF SELECTIVE VITAMIN D RECEPTOR ACTIVATION BY PARICALCITOL IN TYPE 2 DIABETES PATI...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004263-38 Sponsor Protocol Number: VBP-003 Start Date*: 2017-02-13
    Sponsor Name:ReveraGen BioPharma Inc.
    Full Title: A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD)
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004262-26 Sponsor Protocol Number: VBP15-002 Start Date*: 2017-02-13
    Sponsor Name:ReveraGen BioPharma Inc.
    Full Title: A Phase IIa, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys with Duchenne Muscular ...
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000387-14 Sponsor Protocol Number: RM-493-014 Start Date*: 2017-05-24
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity
    Medical condition: - POMC/PCSK1/LEPR heterozygous - POMC/PCSK1/LEPR compound heterozygous or homozygous deficiency obesity - POMC/PCSK1/LEPR composite heterozygous deficiency obesity - Smith-Magenis Syndrome - SH2B1...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) FR (Ongoing) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001057-26 Sponsor Protocol Number: IRFM-7468 Start Date*: 2018-07-19
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Management of the patient with heart failure and diabetes: may insulin be a problem? A pilot randomized clinical study (Insulin-HF).
    Medical condition: Heart failure and diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    20.1 100000004849 10007555 Cardiac failure (NOS) LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002704-27 Sponsor Protocol Number: VBP15-004-A4 Start Date*: 2019-07-06
    Sponsor Name:ReveraGen BioPharma, Inc.
    Full Title: A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne...
    Medical condition: Duchenne muscular dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: BE (Completed) SE (Completed) NL (Completed) CZ (Completed) GR (Completed) ES (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-003568-10 Sponsor Protocol Number: VBP15-LTES Start Date*: 2017-11-23
    Sponsor Name:ReveraGen BioPharma Inc.
    Full Title: A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD)
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: SE (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 12 23:39:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA